Literature DB >> 28893780

Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients.

Alan Forrest1, Samira M Garonzik2, Visanu Thamlikitkul3, Evangelos J Giamarellos-Bourboulis4, David L Paterson5, Jian Li6, Fernanda P Silveira7, Roger L Nation8.   

Abstract

Acute kidney injury (AKI) occurs in a substantial proportion of critically ill patients receiving intravenous colistin. In the pharmacokinetic/toxicodynamic analysis reported here, the relationship of the occurrence of AKI to exposure to colistin and a number of potential patient factors was explored in 153 critically ill patients, none of whom were receiving renal replacement therapy. Tree-based modeling revealed that the rates of AKI were substantially higher when the average steady-state plasma colistin concentration was greater than ∼2 mg/liter.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  PK/TD relationship; acute kidney injury; colistin

Mesh：

Substances：

Year:  2017        PMID： 28893780      PMCID： PMC5655114          DOI： 10.1128/AAC.01367-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin.

Authors:  Hee ja Ko; Min hyok Jeon; Eun ju Choo; Eun jung Lee; Tae hyong Kim; Jae-Bum Jun; Hyo-Wook Gil
Journal:  Nephron Clin Pract       Date:  2010-09-17

3.  Colistin dosing and nephrotoxicity in a large community teaching hospital.

Authors:  C Andrew Deryke; Amanda J Crawford; Nizam Uddin; Mark R Wallace
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

4.  Risk factors for colistin-associated nephrotoxicity.

Authors:  Pinyo Rattanaumpawan; Puangpaka Ungprasert; Visanu Thamlikitkul
Journal:  J Infect       Date:  2010-12-01       Impact factor: 6.072

5.  Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients.

Authors:  Timothy P Gauthier; William R Wolowich; Arathi Reddy; Ennie Cano; Lilian Abbo; Laura B Smith
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

6.  Colistin therapy in critically ill patients with chronic renal failure and its effect on development of renal dysfunction.

Authors:  Melda Turkoglu; Murat Dizbay; Arzu Ciftçi; F Nur Aksakal; Gülbin Aygencel
Journal:  Int J Antimicrob Agents       Date:  2011-11-23       Impact factor: 5.283

7.  Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.

Authors:  Roger L Nation; Jian Li; Otto Cars; William Couet; Michael N Dudley; Keith S Kaye; Johan W Mouton; David L Paterson; Vincent H Tam; Ursula Theuretzbacher; Brian T Tsuji; John D Turnidge
Journal:  Lancet Infect Dis       Date:  2014-10-21       Impact factor: 25.071

8.  Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.

Authors:  S M Garonzik; J Li; V Thamlikitkul; D L Paterson; S Shoham; J Jacob; F P Silveira; A Forrest; R L Nation
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

9.  Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen.

Authors:  Roger Jelliffe
Journal:  Am J Nephrol       Date:  2002 Jul-Aug       Impact factor: 3.754

10.  Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study.

Authors:  Monica Rocco; Luca Montini; Elisa Alessandri; Mario Venditti; Amalia Laderchi; Gennaro De Pascale; Giammarco Raponi; Michela Vitale; Paolo Pietropaoli; Massimo Antonelli
Journal:  Crit Care       Date:  2013-08-14       Impact factor: 9.097
View more
  21 in total

1.  Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency.

Authors:  Peile Wang; Qiwen Zhang; Zhenfeng Zhu; Hui Pei; Min Feng; Tongwen Sun; Jing Yang; Xiaojian Zhang
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 2.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

3.  Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST).

Authors:  Jason M Pogue; Ronald N Jones; John S Bradley; David R Andes; Sujata M Bhavnani; George L Drusano; Michael N Dudley; Robert K Flamm; Keith A Rodvold; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

4.  A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion.

Authors:  Alexis Viel; Jérôme Henri; Salim Bouchène; Julian Laroche; Jean-Guy Rolland; Jacqueline Manceau; Michel Laurentie; William Couet; Nicolas Grégoire
Journal:  Pharm Res       Date:  2018-03-12       Impact factor: 4.200

5.  Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of Klebsiella pneumoniae in a Hollow Fiber Infection Model.

Authors:  G L Drusano; Ryan K Shields; Nino Mtchedlidze; M Hong Nguyen; Cornelius J Clancy; Michael Vicciarelli; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

6.  The Anthelmintic Drug Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli.

Authors:  Ronald Domalaon; P Malaka De Silva; Ayush Kumar; George G Zhanel; Frank Schweizer
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

7.  Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.

Authors:  Luisa Sorlí; Sonia Luque; Jian Li; Núria Campillo; Marc Danés; Milagro Montero; Concha Segura; Santiago Grau; Juan Pablo Horcajada
Journal:  J Infect       Date:  2019-06-29       Impact factor: 6.072

8.  Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.

Authors:  Kevin J Downes; Jennifer L Goldman
Journal:  Clin Pharmacol Ther       Date:  2021-02-27       Impact factor: 6.875

9.  Short-Course Versus Long-Course Colistin for Treatment of Carbapenem-Resistant A.baumannii in Cancer Patient.

Authors:  Wasan Katip; Suriyon Uitrakul; Peninnah Oberdorfer
Journal:  Antibiotics (Basel)       Date:  2021-04-22

10.  International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).

Authors:  Brian T Tsuji; Jason M Pogue; Alexandre P Zavascki; Mical Paul; George L Daikos; Alan Forrest; Daniele R Giacobbe; Claudio Viscoli; Helen Giamarellou; Ilias Karaiskos; Donald Kaye; Johan W Mouton; Vincent H Tam; Visanu Thamlikitkul; Richard G Wunderink; Jian Li; Roger L Nation; Keith S Kaye
Journal:  Pharmacotherapy       Date:  2019-01       Impact factor: 6.251
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.